Latest News

Press Releases

Date

Title and Summary

View/Download

July 15, 2017 Akaal Pharma Initiates Phase-2 Clinical Trial of Topical AKP-11 for the Treatment of Atopic Dermatitis (Eczema) download PDF
Dec 7, 2016 Akaal Pharma to Attend 35th J. P. Morgan Healthcare Conference download PDF
Sep 14, 2016 China Patent Granted to Akaal Pharma on S1P1 Receptor Modulators for the Treatment of Immune and Inflammatory Diseases download PDF
Sep 12, 2016 Japan Patent Granted to Akaal Pharma on S1P1 Receptor Modulators for Immune and Inflammatory Diseases download PDF
Jun 22, 2016 European Patent Granted to Akaal Pharma on S1P1 Receptor Modulators for Immune and Inflammatory Diseases download PDF
Mar 7, 2016 AKP-11 poster presented at ACTRIMS Forum 2016 Meeting in New Orleans, LA, USA. download PDF
Dec 10, 2015 Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis. View Html || download PDF
Dec 07, 2015 US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases. View Html || download PDF
Jun 16, 2015 Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis. View Html || download PDF
Jan 29, 2015 Akaal Pharma Announces Positive Results from Phase 1 Clinical Study of Novel Topical AKP-11 for the Treatment of Psoriasis. View Html || download PDF
Jan 19, 2015 Akaal Pharma’s Australian patent accepted for S1P1 Receptor Modulators Useful in the Treatment of Autoimmune and Inflammatory Diseases. download PDF
Nov 26, 2013 US Patent Issued to Akaal Pharma Pty Ltd on S1P1 Receptor Modulators Useful in the Treatment of Autoimmune and Inflammatory Diseases. download PDF